Scientist II, Advanced Research — MRD cfDNA NGS

SRG; Cambridge; On-site; GBP 45,000 - 65,000; Full time

Job summary

SRG in Cambridge is seeking a Scientist II, Advanced Research to join a small early research team. You will help develop next generation technologies for detecting minimal residual disease in cancer patients using circulating tumour DNA, advancing the method from early research through optimisation to a viability assessment.

This hands-on role works closely with computational colleagues to translate requirements into analytical specs and troubleshoot discrepancies between wet lab and data.

Qualifications

• PhD preferred in life, physical or computational science.
• Minimum 2 years of applied molecular (NGS) experience.
• Hands-on NGS library preparation experience.
• Strong lab skills in library construction and molecular biology.
• Knowledge of cancer biology and cancer genomics.
• Ability to troubleshoot complex experimental systems.
• Experience with cfDNA/ctDNA analysis or error suppression approaches.
• Experience with cancer diagnostics or liquid biopsy is desirable.

Responsibilities

• Refine and execute a programme of research and optimisation experiments for a novel cell-free DNA MRD detection method.
• Independently perform complex and novel library preparation and next generation sequencing workflows.
• Carry out supporting work such as blood processing and cfDNA extractions.
• Diagnose and resolve experimental problems, elevate appropriately and timely.
• Analyse and interpret sequencing data in collaboration with computational colleagues, defining analytical requirements.
• Maintain complete, accurate and contemporaneous experimental records suitable for regulatory and patent purposes.

Skills

NGS library prep

Troubleshooting

Cancer genomics

cfDNA ctDNA

Sequencing data analysis

Education

PhD preferred

Job description

SRG in Cambridge is seeking a Scientist II, Advanced Research to join a small early research team. You will help develop next generation technologies for detecting minimal residual disease in cancer patients using circulating tumour DNA, advancing the method from early research through optimisation to a viability assessment.

This hands-on role works closely with computational colleagues to translate requirements into analytical specs and troubleshoot discrepancies between wet lab and data.